Research programme: autologous T cell therapies - TxCell

Drug Profile

Research programme: autologous T cell therapies - TxCell

Alternative Names: Ag-Treg therapeutics - TxCell; Balancell; CAR engineered CD4+ Treg cells - TxCell; CAR-Treg-TxCell; CD4+ CD25+ CD45RA+ Tregs; CD45RA+ Tregs; CellArthrix; Col-Treg-TxCell; ENTrIA; ENTX-BP; ENTX-LN; ENTX-MS; ENTX-SOT; HLA-A2 CAR-Treg - TxCell; HSP60-Treg-TxCell; Myelin-Treg-TxCell; Tr1 cell therapy - TxCell; TX 200; TX-MSD

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Ospedale San Raffaele; University of British Columbia; University of Lubeck; Weizmann Institute of Science
  • Class CAR-T cell therapies; Cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immune-mediated uveitis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bullous pemphigoid; Transplant rejection
  • Research Lupus nephritis
  • No development reported Autoimmune disorders; Immune-mediated uveitis

Most Recent Events

  • 31 May 2018 TxCell announces intention to submit a CTA for TX 200 in the first part of 2019
  • 28 Feb 2018 No recent reports of development identified for preclinical development in Immune-mediated-uveitis in France (IV)
  • 26 Sep 2017 Pharmacodynamic results from a preclinical study in Transplant rejection presented at the18th Congress of the European Society for Organ Transplantation (ESOT-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top